抗CD20治疗在神经免疫突破性疾病中的挽救治疗 - Suppr

Suppr

超能文献

Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.

作者信息

Chan Andrew, Lee De-Hyung, Linker Ralf, Mohr Alexander, Toyka Klaus V, Gold Ralf

出版信息

J Neurol. 2007 Nov;254(11):1604-6. doi: 10.1007/s00415-007-0593-9. Epub 2007 Aug 27.

DOI:10.1007/s00415-007-0593-9

PMID:17713826

Abstract

摘要

相似文献

Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.

J Neurol. 2007 Nov;254(11):1604-6. doi: 10.1007/s00415-007-0593-9. Epub 2007 Aug 27.

[A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].

Rinsho Shinkeigaku. 2015;55(4):227-32. doi: 10.5692/clinicalneurol.55.227.

Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma.

Ann Hematol. 2005 Aug;84(8):548-50. doi: 10.1007/s00277-005-1050-4. Epub 2005 May 4.

Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.

J Clin Neuromuscul Dis. 2011 Mar;12(3):163-4. doi: 10.1097/CND.0b013e3181df2b3e.

Double seropositive myasthenia gravis with acetylcholine receptor and lipoprotein receptor-related protein 4 antibodies.

Muscle Nerve. 2014 Jun;49(6):930-1. doi: 10.1002/mus.24166.

Myasthenia gravis: immune mechanisms and implications.

Clin Exp Neurol. 1981;18:14-26.

Myasthenia gravis: a model disorder of acetylcholine receptors.

Res Publ Assoc Res Nerv Ment Dis. 1987;65:65-82.

[Amount of circulating acetylcholine receptor antibodies in the course of myasthenia, following thymectomy and in immunosuppressive therapy].

Nervenarzt. 1984 Aug;55(8):426-31.

Humoral immunity in myasthenia gravis: relationship to disease severity and steroid treatment.

Prog Brain Res. 1979;49:441-8. doi: 10.1016/S0079-6123(08)64656-7.

Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.

Neurology. 2011 Feb 22;76(8):757-8. doi: 10.1212/WNL.0b013e31820d6290.

引用本文的文献

Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.

J Neurol. 2022 Aug;269(8):4229-4240. doi: 10.1007/s00415-022-11048-4. Epub 2022 Mar 3.

Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis.

Ther Adv Neurol Disord. 2019 Sep 18;12:1756286419871187. doi: 10.1177/1756286419871187. eCollection 2019.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17.

Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease.

Cell Stem Cell. 2016 Jan 7;18(1):134-43. doi: 10.1016/j.stem.2015.10.002. Epub 2015 Nov 5.

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

J Neurol. 2015 May;262(5):1115-9. doi: 10.1007/s00415-014-7532-3. Epub 2014 Oct 12.

Innovative monoclonal antibody therapies in multiple sclerosis.

Ther Adv Neurol Disord. 2008 Jul;1(1):43-52. doi: 10.1177/1756285608093945.

Practical considerations on the use of rituximab in autoimmune neurological disorders.

Ther Adv Neurol Disord. 2010 Mar;3(2):93-105. doi: 10.1177/1756285609356135.

Diagnosis and management of autoimmune myasthenia gravis.

Clin Drug Investig. 2011;31(1):1-14. doi: 10.2165/11584740-000000000-00000.

[Rituximab in treatment for neuroimmunological diseases].

Nervenarzt. 2009 Feb;80(2):155-6, 158-60, 162-5. doi: 10.1007/s00115-008-2663-3.

Current and future standards in treatment of myasthenia gravis.

Neurotherapeutics. 2008 Oct;5(4):535-41. doi: 10.1016/j.nurt.2008.08.011.

本文引用的文献

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.

Ann Neurol. 2006 Jun;59(6):880-92. doi: 10.1002/ana.20890.

B cell immunobiology in disease: evolving concepts from the clinic.

Annu Rev Immunol. 2006;24:467-96. doi: 10.1146/annurev.immunol.24.021605.090517.

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Arch Neurol. 2005 Oct;62(10):1620-3. doi: 10.1001/archneur.62.10.1620.

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Lancet. 2005;366(9485):579-82. doi: 10.1016/S0140-6736(05)67102-4.

An open label study of the effects of rituximab in neuromyelitis optica.

Neurology. 2005 Apr 12;64(7):1270-2. doi: 10.1212/01.WNL.0000159399.81861.D5.

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

Arch Neurol. 2005 Feb;62(2):258-64. doi: 10.1001/archneur.62.2.258.

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

Trends Mol Med. 2001 Mar;7(3):115-21. doi: 10.1016/s1471-4914(00)01909-2.

Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.

Transfus Sci. 1998 Mar;19 Suppl:43-6. doi: 10.1016/s0955-3886(97)00102-1.

Myasthenia gravis: remission not induced by blocking anti-idiotype antibodies.

Muscle Nerve. 1983 Jun;6(5):386-7. doi: 10.1002/mus.880060508.

Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

Neurology. 1983 Oct;33(10):1316-21. doi: 10.1212/wnl.33.10.1316.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验